* Bioventus Inc BVS.OQ BVS.O is expected to show a rise
in
quarterly revenue when it reports results on August 6 for the
period ending June 30 2024
* The Durham North Carolina-based company is expected to
report a
0.4% increase in revenue to $137.595 million from $137.07
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Bioventus Inc is for
earnings
of 7 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bioventus
Inc is
$8.50, above its last closing price of $7.00.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.06 -0.07 0.07 Beat 193.3
Dec. 31 2024 0.05 0.02 0.07 Beat 250
Sep. 30 2023 -0.02 -0.02 0.05 Beat 350
Jun. 30 2023 0.01 0.00 0.14 Beat
Mar. -0.15 -0.15 -0.26 Missed -73.3
31 2023
Dec. 31 2022 0.05 0.05 -0.06 Missed -226.3
Jan. 1 0001 0.12 0.12 0.08 Missed -34.4
Jun. 30 2022 0.15 0.16 0.10 Missed -35.9
This summary was machine generated August 2 at 14:37 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)